Cell-based therapeutics are an emerging modality with the potential to treat many currently
intractable diseases through uniquely powerful modes of action. Despite notable recent …

The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs)
has the potential to provide an unlimited source of insulin-producing β cells for the treatment …

Genetic engineering of allogeneic cell therapeutics that fully prevents rejection by a
recipient's immune system would abolish the requirement for immunosuppressive drugs or …

Insulin-producing β cells created from human pluripotent stem cells have potential as a
therapy for insulin-dependent diabetes, but human pluripotent stem cell-derived islets (SC …

Transplantation of allogeneic pancreatic donor islets has successfully been performed in
selected patients with difficult-to-control insulin-dependent diabetes and impaired …

Understanding pancreas development can provide clues for better treatments of pancreatic
diseases. However, the molecular heterogeneity and developmental trajectory of the early …

Diabetes involves the death or dysfunction of pancreatic β-cells. Analysis of bulk sequencing
from human samples and studies using in vitro and in vivo models suggest that endoplasmic …

Type 1 diabetes mellitus (T1D) is a chronic disease characterized by an autoimmune
destruction of insulin-producing β-pancreatic cells. Although many advances have been …

A promising cell-therapy approach for heart failure aims at differentiating human pluripotent
stem cells (hPSCs) into functional cardiomyocytes (CMs) in vitro to replace the disease …

The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D)
relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as …